Research status of clinical application of recombinant human urokinase
10.3760/cma.j.cn115396-20240223-00046
- VernacularTitle:重组人尿激酶原的临床应用研究现状
- Author:
Zixing LI
1
;
Liqi YI
;
Zhanfeng GAO
Author Information
1. 内蒙古医科大学附属医院血管外科，呼和浩特 010059
- Keywords:
Thrombolytic therapy;
Thromboembolism;
Drug-eluting stents;
Acoustic microbubbles;
Recombinant human urokinase
- From:
International Journal of Surgery
2024;51(3):212-216
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, recombinant human urokinase (rhPro-UK) has been widely used in the treatment of a variety of thromboembolic diseases, with significant efficacy and no obvious adverse reactions. In addition, it has a wide range of applications in many new technology fields. This article focuses on the application of rhPro-UK in the treatment of acute myocardial infarction, cerebrovascular disease, lower extremity deep vein thrombosis, arterial thrombosis and other diseases. rhPro-UK has demonstrated good thrombolytic efficacy and safety in these diseases, especially in patients with acute myocardial infarction, and adjuvant PCI therapy can significantly increase myocardial reperfusion, improve cardiac function, and do not increase the risk of bleeding. For cerebrovascular disease, rhPro-UK can significantly improve the degree of neurological deficit and has a high safety profile. In the treatment of lower extremity deep vein thrombosis, rhPro-UK has shown superior thrombolytic efficacy and safety compared with urokinase. For arterial thrombosis and biological stents, the use of rhPro-UK has also achieved some efficacy, but more research is needed to confirm its efficacy and safety. In addition, ultrasound-mediated drug-loaded thrombolysis systems also have potential applications in rhPro-UK therapy. Future research on rhPro-UK will focus more on the development of new technologies.
